<DOC>
	<DOCNO>NCT02689856</DOCNO>
	<brief_summary>The objective study assess potential contribution lidocaine hydrochloride hydrocortisone acetate , alone combination , topical cream preparation treatment Grade I II hemorrhoid demonstrate safety efficacy test article apply twice daily 14 day subject Grade I II hemorrhoid . These product reflect common drug combination lidocaine hydrochloride hydrocortisone acetate find many prescription hemorrhoid product .</brief_summary>
	<brief_title>Safety Efficacy Hydrocortisone Lidocaine Treatment Grade I II Hemorrhoids</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , parallel group comparison study approximately 196 enrolled subject ( ~28 subjects/test article ) approximately eight ( 8 ) site . A minimum 147 patient enrol . Up additional 56 subject ( 196 subject ) may enrol base enrollment rate availability patient . Enrollment status report periodically generate , base enrollment experience , additional randomization block assign sit potential enroll additional subject reasonable period time . Male female subject , age 18 year old , clinical diagnosis symptomatic Grade I Grade II hemorrhoid randomize treatment one seven ( 7 ) test article ( 1:1 group ) : 1 . Vehicle Cream 2 . 3 % Hydrocortisone Acetate Cream 3 . 0.5 % Hydrocortisone Acetate Cream 4 . 5 % Lidocaine Hydrochloride Cream 5 . 1 % Lidocaine Hydrochloride Cream 6 . 3 % Hydrocortisone Acetate Cream 5 % Lidocaine Hydrochloride Cream 7 . 0.5 % Hydrocortisone Acetate Cream 1 % Lidocaine Hydrochloride Cream The test article apply twice daily two ( 2 ) week ( 14 day ) peri-rectal area well distal aspect anal canal use product applicator tip .</detailed_description>
	<mesh_term>Hemorrhoids</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>1 . Subject male nonpregnant female 18 year age older , generally good health . Females must postmenopausal , surgically sterile negative urine pregnancy test ( UPT ) Baseline Visit agree use birth control study . 2 . Subject provide write verbal informed consent . 3 . Subject present clinic clinically confirm symptomatic Grade I II hemorrhoid ( GSDS â‰¥ 2 ) . 4 . Subject willing able comply study instruction return clinic require visit . 1 . Subject female lactating planning become pregnant study . 2 . Subject anorectal condition ( ) malignant tumor anus rectum , fistulainano chronic sepsis , fissureinano , incontinence , condylomata Grade III IV hemorrhoid . 3 . Subject history previous proctological surgery active inflammatory bowel disease . 4 . Subject may use stool softener , shall stable regimen least 28 day prior enrol study . 5 . Subject use follow systemic , oral topical therapy period specify prior entry study : Within 1 day : Topicals kind rectal/perirectal area . Within 1 week : Over counter ( OTC ) prescription treatment label intend treatment hemorrhoid could significant effect opinion investigator include limited steroid , OTC prescription hemorrhoid product , among others . 6 . Subject current history uncorrected coagulation defect concurrently use anticoagulant ( except aspirin nonsteroidal ) . 7 . Subject skin pathology condition could interfere evaluation test product require use interfere topical , systemic surgical therapy . 8 . Subject know hypersensitivity previous allergic reaction active inactive component test article . 9 . Subject condition , Investigator 's opinion , would make unsafe preclude subject 's ability fully participate research study . 10 . Subject unable communicate cooperate Investigator due language problem , poor mental development , impaired cerebral function physical limitation . 11 . Subject may unreliable study include subject engage excessive alcohol intake drug abuse , subject unable return schedule followup visit . 12 . Subject currently enrol investigational drug device study . 13 . Subject receive investigational drug treat investigational device within 30 day prior initiation treatment ( Baseline ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>